Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06788938 · ClinicalTrials.gov registry record · Phase 2
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
A Phase 2 study of Advanced Tumors and DLL3-expressing Tumors, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 5
- Study locations
NCT06788938: Recruiting Phase 2 study of Advanced Tumors and DLL3-expressing Tumors, sponsored by Jonsson Comprehensive Cancer Center.
NCT06788938 is a Phase 2 study of Advanced Tumors and DLL3-expressing Tumors that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06788938, a Phase 2 study of Advanced Tumors and DLL3-expressing Tumors, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for tumors and is FDA-approved for extensive-stage small cell lung cancer. Tarlatamab is investigational for the purpose of this study.
Conditions Studied
Interventions
- DRUG Tarlatamab treatment
Study Locations (5)
California
- UC Davis Comprehensive Cancer Center - Davis
- UCI Health Chao Family Comprehensive Cancer Center - Irvine
- University of California at Los Angeles - Los Angeles
- UC San Diego Moores Cancer Center - San Diego
- University of California at San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2029-04-24 |
| Phase | Phase 2 |
What NCT06788938 shows while recruiting
NCT06788938 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Advanced Tumors appearing as the primary indexed condition, and to 1 intervention - of which Tarlatamab treatment is the first listed.
NCT06788938 lists 5 locations in 1 state (California).
Frequently Asked Questions
What is clinical trial NCT06788938 about?
NCT06788938 is a clinical study titled "Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms". This study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for...
What is the current status of trial NCT06788938?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2025-03-21. Estimated completion is 2029-04-24.
What conditions does trial NCT06788938 study?
This clinical trial studies the following conditions: Advanced Tumors, DLL3-expressing Tumors.
What interventions are being tested in trial NCT06788938?
The interventions under investigation include: Tarlatamab treatment (DRUG).
Who is sponsoring clinical trial NCT06788938?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06788938 being conducted?
This trial has 5 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06788938's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI